Features | Partner Sites | Information | LinkXpress
Sign In
KOREA E & EX
Schiller
Ampronix

Zoll Acquires Intellectual Assets of Coaxia

By HospiMedica International staff writers
Posted on 15 Jul 2013
ZOLL (Chelmsford, MA, USA) has purchased the assets of CoAxia (Maple Grove, MN, USA), an early revenue stage medical device company that provides catheter-based perfusion augmentation therapies.

The core application ofCoAxia’s catheter technology, distributed under the trade names NeuroFlo and FloControl, involves the redistribution of blood flow from the lower extremities to support brain function during cerebral ischemia resulting from vasospasm, following subarachnoid hemorrhage. CoAxia did not have the funds to continue development after its de novo petition for the NeuroFlo catheter was rejected by the US Food and Drug Administration (FDA) for acute ischemic stroke. Zoll, however, still sees opportunity for the device and plans to design a new pivotal trial to take before the FDA.

Both NeuroFlo and FloControl blood flow redistribution technology use dual balloons to create temporary partial obstruction in the descending aorta. This technique causes a redistribution of cardiac output from the lower extremities to the cerebral vasculature without significantly increasing arterial blood pressure. The acquisition of the intellectual property also includes several key patents on cerebral perfusion augmentation as well as numerous other patents relevant to other various vascular procedures. Financial terms of the purchase were not disclosed.

“NeuroFlo technology has the potential to address a large portion of the population who suffer cerebral ischemia, offering a significant benefit to patients and the healthcare system,” said James Palazzolo, president of Zoll. “Our task is to continue to develop the significant body of clinical evidence started by CoAxia demonstrating the safety and efficacy of the NeuroFlo catheter and, in the end, do what is necessary for it to be a standard treatment option for hundreds of thousands of stroke patients worldwide.”

The acquisition of CoAxia’s intellectual property also offers synergy with Zoll’s acute critical care portfolio of products such as temperature management, which may reduce reperfusion injury following ischemia by using balloon catheters. The devices could also offer significant potential applications in blood flow redistribution for trauma, cardiac arrest, coronary procedures, surgical blood loss, and renal perfusion.

Related Links:

ZOLL
CoAxia



Anetic Aid
Inditherm
JD Honigberg International
RG Advertising

Channels

Critical Care

view channel

Little Evidence Supports Opioid Use for Chronic Pain

A new study reveals that there is paltry evidence for the long-term safety and efficacy of opioids in the treatment of chronic pain. Researchers at the Oregon Health & Science University (OHSU; Portland, USA) and the University of Washington (Seattle, USA) searched MEDLINE, the Cochrane Central Register of Controlled... Read more

Surgical Techniques

view channel

Epidural Steroid Injections Could Help Avoid Surgery

For patients with lower back pain, epidural steroid injections (ESI) could reduce the need for surgery, according to a new study. Researchers at Massachusetts General Hospital (Boston, USA) conducted a systematic review and meta-analysis of studies to determine whether ESI could have a surgery-sparing effect in patients... Read more

Women's Health

view channel

Pregnant Women in Austria Experience Iodine Deficiency

A new study suggests that pregnant women in Austria have a potentially clinically significant iodine deficiency which could impair embryonic brain development. Researchers at the Medical University of Vienna (Austria) conducted a cross-sectional investigation of urinary iodine excretion in 246 pregnant women (2 in the... Read more

Health IT

view channel

Computer Model Predicts Public Response to Disease Outbreaks

A new computer model could help public health officials anticipate public reactions to disease outbreaks, based on a combination of data collected from hospitals, social media, and other sources. Researchers at MIT (Cambridge, MA, USA), the Draper Laboratory (Cambridge, MA, USA), and Ascel Bio (Larchmont, NY, USA),... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.